CA2210500A1 - Therapeutic compound - fatty acid conjugates - Google Patents
Therapeutic compound - fatty acid conjugatesInfo
- Publication number
- CA2210500A1 CA2210500A1 CA002210500A CA2210500A CA2210500A1 CA 2210500 A1 CA2210500 A1 CA 2210500A1 CA 002210500 A CA002210500 A CA 002210500A CA 2210500 A CA2210500 A CA 2210500A CA 2210500 A1 CA2210500 A1 CA 2210500A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- compound
- group
- family
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPN0582 | 1995-01-16 | ||
AUPN0585 | 1995-01-16 | ||
AUPN0580A AUPN058095A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 2 |
AUPN0584A AUPN058495A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 6 |
AUPN0586A AUPN058695A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 8 |
AUPN0583 | 1995-01-16 | ||
AUPN0582A AUPN058295A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 4 |
AUPN0585A AUPN058595A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 7 |
AUPN0584 | 1995-01-16 | ||
AUPN0581 | 1995-01-16 | ||
AUPN0581A AUPN058195A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 3 |
AUPN0583A AUPN058395A0 (en) | 1995-01-16 | 1995-01-16 | Therapeutic conjugates 5 |
AUPN0586 | 1995-01-16 | ||
AUPN0580 | 1995-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2210500A1 true CA2210500A1 (en) | 1996-07-25 |
Family
ID=27560724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002210500A Abandoned CA2210500A1 (en) | 1995-01-16 | 1996-01-15 | Therapeutic compound - fatty acid conjugates |
Country Status (10)
Country | Link |
---|---|
US (3) | US5952499A (sv) |
EP (1) | EP0804459A4 (sv) |
JP (1) | JPH11502509A (sv) |
BR (1) | BR9607492A (sv) |
CA (1) | CA2210500A1 (sv) |
FI (1) | FI973002A (sv) |
NO (1) | NO973283L (sv) |
NZ (1) | NZ298712A (sv) |
RU (1) | RU2166512C2 (sv) |
WO (1) | WO1996022303A1 (sv) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2713838C1 (ru) * | 2019-04-23 | 2020-02-07 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Способ анестезиологического обеспечения при селективной доставке химиопрепарата к сетчатке глаза при лечении интраокулярной ретинобластомы у детей |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
AUPN741696A0 (en) * | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
DE19631189A1 (de) * | 1996-08-02 | 1998-02-05 | Max Delbrueck Centrum | Neuartige kationische Amphiphile für den liposomalen Gentransfer |
US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
BR9913285A (pt) * | 1998-08-31 | 2001-05-15 | Biogen Inc | Método de modulação das células t efetoras da memória e composições |
AUPP751398A0 (en) * | 1998-12-04 | 1999-01-07 | Commonwealth Scientific And Industrial Research Organisation | Methotrexate derivatives |
US7235583B1 (en) * | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
US7238368B2 (en) | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
WO2000064484A2 (en) * | 1999-04-23 | 2000-11-02 | Alza Corporation | Conjugate having a cleavable linkage for use in a liposome |
US6765019B1 (en) * | 1999-05-06 | 2004-07-20 | University Of Kentucky Research Foundation | Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids |
AU761544C (en) * | 1999-05-24 | 2004-02-12 | Sankyo Company Limited | Medicinal compositions containing anti-Fas antibody |
GB9930026D0 (en) * | 1999-12-21 | 2000-02-09 | Univ Sheffield | Novel compounds of unsaturated fatty acids |
US6485740B1 (en) * | 2000-03-14 | 2002-11-26 | Yutoku Pharmaceutical Ind., Co., Ltd. | Transdermal methotrexate preparations |
EP1427407A4 (en) * | 2001-03-23 | 2005-05-11 | Luitpold Pharm Inc | CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS |
ES2387562T3 (es) * | 2001-03-23 | 2012-09-26 | Luitpold Pharmaceuticals, Inc. | Conjugados alcohol graso-medicamento |
BR0210179A (pt) * | 2001-06-05 | 2004-04-27 | Control Delivery Sys Inc | Compostos analgésicos de liberação sustentada |
WO2003009740A2 (en) * | 2001-07-24 | 2003-02-06 | Biogen Idec Ma Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
US7125568B2 (en) | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
US7045543B2 (en) | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
KR100915284B1 (ko) * | 2003-09-30 | 2009-09-03 | 샤이어 엘엘씨 | 과용 또는 남용을 예방하기 위한 제약 조성물 |
WO2005077018A2 (en) * | 2004-02-06 | 2005-08-25 | Astellas Us Llc | Methods of treating skin disorders |
CN1997756A (zh) * | 2004-05-04 | 2007-07-11 | 杰耐萨斯药品公司 | 单倍型标记和利用其确定对于治疗的反应的方法 |
EP1750747A1 (en) * | 2004-05-07 | 2007-02-14 | Astellas US LLC | Soluble lfa-3 polypeptide for treating viral disorders |
US7740875B2 (en) * | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
WO2006085149A2 (en) | 2004-12-22 | 2006-08-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
CN101360986A (zh) * | 2005-12-16 | 2009-02-04 | 印第安纳大学研究及科技有限公司 | 亚微米表面等离子体激元谐振传感器系统 |
JP5607930B2 (ja) | 2006-10-12 | 2014-10-15 | ビーエイチアイ リミテッド パートナーシップ | 3−アミノ−1−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体 |
US8710069B2 (en) * | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-nornicotine codrugs combinations for pain management |
US8710070B2 (en) * | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
US20110178024A1 (en) | 2008-09-29 | 2011-07-21 | Ben Gurion University Of The Negev Research And Development Authority | Amyloid beta-peptides and methods of use thereof |
EP2349241B1 (en) * | 2008-10-17 | 2019-06-19 | Signature Therapeutics, Inc. | Pharmaceutical compositions with attenuated release of phenolic opioids |
EP2393472B1 (en) | 2008-12-05 | 2019-06-05 | NanoMed Holdings Pty Ltd | Amphiphile prodrugs |
WO2010107487A2 (en) * | 2009-03-18 | 2010-09-23 | Wu Nian | Lipid-drug conjugates for drug delivery |
EP2531221B1 (en) | 2010-02-03 | 2019-03-13 | IC Discovery GmbH | Polyanionic multivalent macromolecules for intracellular targeting of proliferation and protein synthesis |
WO2013063204A1 (en) | 2011-10-26 | 2013-05-02 | Kempharm, Inc. | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof |
CA2969221C (en) | 2014-12-02 | 2021-01-12 | Travis Mickle | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof |
ES2954596T3 (es) * | 2015-12-23 | 2023-11-23 | Univ British Columbia | Profármacos unidos a lípidos |
JP2020523035A (ja) | 2017-06-07 | 2020-08-06 | エーディーアールエックス, インコーポレイテッド | タウ凝集阻害剤 |
EP3668886A2 (en) | 2017-08-18 | 2020-06-24 | Adrx, Inc. | Tau aggregation peptide inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3686238A (en) * | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4939174A (en) * | 1988-02-26 | 1990-07-03 | Shashoua Victor E | Appetite suppression with dopamine-fatty acid conjugates |
DE3904119A1 (de) * | 1989-02-11 | 1990-08-16 | Hoechst Ag | Polymerfixiertes methotrexat, verfahren zur herstellung und verwendung |
EP0506748B1 (en) * | 1989-12-22 | 1995-12-13 | Commonwealth Scientific And Industrial Research Organisation | Amino acids, peptides or derivatives thereof coupled to fats |
US5583198A (en) * | 1989-12-22 | 1996-12-10 | Commonwealth Scientific And Industrial Research Organization | Amino acids, peptides or derivatives thereof coupled to fats |
JPH0421694A (ja) * | 1990-05-16 | 1992-01-24 | Asahi Chem Ind Co Ltd | 新規なヌクレオシド―リン脂質複合体 |
JPH06509559A (ja) * | 1991-03-19 | 1994-10-27 | セラピューティック パッチ リサーチ エヌ.ブイ. | 膜透過エンハンサーとしてのアミノアルコール誘導体組成物及び方法 |
CA2114125A1 (en) * | 1991-07-26 | 1993-02-18 | Wayne G. Reilly | Self-adjuvanting peptide vaccine delivery system and production thereof |
DE4311987A1 (de) * | 1993-04-07 | 1994-10-13 | Schering Ag | Neue Glucocorticoide |
DE69426629T2 (de) * | 1993-08-02 | 2001-08-02 | Commw Scient Ind Res Org | Therapeutische verbindung - fettsäurekonjugate |
-
1996
- 1996-01-15 US US08/875,098 patent/US5952499A/en not_active Expired - Fee Related
- 1996-01-15 RU RU97113473/04A patent/RU2166512C2/ru not_active IP Right Cessation
- 1996-01-15 CA CA002210500A patent/CA2210500A1/en not_active Abandoned
- 1996-01-15 EP EP96900469A patent/EP0804459A4/en not_active Withdrawn
- 1996-01-15 WO PCT/AU1996/000015 patent/WO1996022303A1/en not_active Application Discontinuation
- 1996-01-15 NZ NZ298712A patent/NZ298712A/xx unknown
- 1996-01-15 BR BR9607492A patent/BR9607492A/pt not_active IP Right Cessation
- 1996-01-15 JP JP8521914A patent/JPH11502509A/ja not_active Ceased
-
1997
- 1997-07-15 NO NO973283A patent/NO973283L/no not_active Application Discontinuation
- 1997-07-15 FI FI973002A patent/FI973002A/sv unknown
-
1999
- 1999-04-12 US US09/289,715 patent/US6281376B1/en not_active Expired - Fee Related
-
2001
- 2001-05-24 US US09/863,385 patent/US20030023104A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2713838C1 (ru) * | 2019-04-23 | 2020-02-07 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Способ анестезиологического обеспечения при селективной доставке химиопрепарата к сетчатке глаза при лечении интраокулярной ретинобластомы у детей |
Also Published As
Publication number | Publication date |
---|---|
EP0804459A1 (en) | 1997-11-05 |
US5952499A (en) | 1999-09-14 |
JPH11502509A (ja) | 1999-03-02 |
US6281376B1 (en) | 2001-08-28 |
BR9607492A (pt) | 1999-06-29 |
NO973283L (no) | 1997-09-08 |
WO1996022303A1 (en) | 1996-07-25 |
EP0804459A4 (en) | 1999-05-26 |
NZ298712A (en) | 1998-12-23 |
FI973002A (sv) | 1997-08-19 |
US20030023104A1 (en) | 2003-01-30 |
FI973002A0 (sv) | 1997-07-15 |
NO973283D0 (no) | 1997-07-15 |
RU2166512C2 (ru) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5952499A (en) | Therapeutic compound-fatty acid conjugates | |
AU618995B2 (en) | Pharmaceutical formulations for parenteral use | |
RU2724436C1 (ru) | Способ получения промежуточного соединения конъюгата антитело-лекарственное средство | |
Paranjpe et al. | Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation | |
EP0110955B1 (en) | Brain-specific drug delivery | |
KR0180245B1 (ko) | 10,11-메틸렌디옥시-20(rs)-캠프토테신 및 10,11-메틸렌디옥시-20(s)-캠프토테신 동족체 | |
Dal Pozzo et al. | Novel tumor-targeted RGD peptide–camptothecin conjugates: Synthesis and biological evaluation | |
WO2017210288A1 (en) | Antibody drug conjugates having derivatives of amatoxin as the drug | |
NZ273952A (en) | Copolymer of n-(2-hydroxypropyl)methacryloylamide and n-methacryloylglycine derivative having camptothecin bound through a spacer to some of the glycine residues | |
WO2007112348A2 (en) | Prodrug composition | |
Pignatello et al. | Lipophilic methotrexate conjugates with antitumor activity | |
AU2020204250B2 (en) | One-pot process for preparing intermediate of antibody-drug conjugate | |
JP4467888B2 (ja) | アロエ−エモジン誘導体と腫瘍性病理学の治療におけるその使用 | |
SK154899A3 (en) | 20(s)- camptothecin glycoconjugates, method for their producing, their use and drugs containing said substances | |
US20220251126A1 (en) | Anticancer agents | |
PIGNATELLO et al. | Aliphatic α, γ‐bis (Amides) of Methotrexate. Influence of Chain Length on In‐vitro Activity Against Sensitive and Resistant Tumour Cells | |
AU709252B2 (en) | Therapeutic compound - fatty acid conjugates | |
JPS6260394B2 (sv) | ||
Poulos et al. | Structure activity studies on the C-terminal hexapeptide of substance P with modifications at the glutaminyl and methioninyl residues | |
EP2405944B1 (en) | Prodrugs | |
KR19980701552A (ko) | 치료용 화합물-지방산 접합체(therapeutic compounds-fatty acid conjugates) | |
EP1135390A1 (en) | Methotrexate derivatives | |
O'Driscoll et al. | Clofazimine | |
EP3598982A1 (en) | Bioconjugates of neuropeptides derivatives | |
JPH11269195A (ja) | ペプチド誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |